Top officials from fire wings of three Maharashtra government agencies on Friday launched a probe to ascertain the cause of the blaze that killed five workers at Serum Institute of India's premises here.
Heads of fire departments of the Pune Municipal Corporation (PMC), Pune Metropolitan Region Development Authority (PMRDA) and Maharashtra Industrial Development Corporation (MIDC) are part of the joint probe team.
Five contractual labourers had died in the fire which broke out in a five-storeyed under-construction building in the Serum Institute of India's Manjari premises on Thursday. The fire damaged the top two floors of the building located in 'SEZ 3' area of the premises of the vaccine major.
Devendra Potphode, Chief Fire Officer, PMRDA, said officials from the planning and development authority, PMC, and MIDC have come together to ascertain the cause of the fire in the building.
Meanwhile, police have registered an accidental death and burning incident case with the Hadapsar police station, said Deputy Commissioner of Police (Zone 5) Namrata Patil.
"As we are seeing today, theentire floor (4th and 5th) has been damaged. We are trying to ascertain the cause of thefire as well as how the fire spread," said Potphode.
Several types of equipmentwere damaged in the blaze, he said.
"On the basis of findings from all the agencies, a conclusion will be reached on a how the fire started," he added.
The PMRDA officer declined to speculate on possible causes of the fire at this juncture.
Santosh Warrick, Chief Fire Officer, MIDC, also said it is difficult to comment on the cause right now.
"We have started the probe. Our scope of investigation is to check how the fire broke out," said Prashant Ranpise, PMC's fire department head.
A team of forensic experts reached the spot and conducting their probe, said another official.
The Manjari facility is where Covishield, the SII vaccine against COVID-19, which is being used in the nationwide inoculation drive against the infection, is made.
The building where fire broke out is one km from the Covishield vaccine manufacturing unit.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)